879-57-2

Basic information

• Product Name: 2-ETHOXY-N-HYDROXY-BENZAMIDINE
• Synonyms: 2-ETHOXY-N-HYDROXY-BENZAMIDINE;Imidoxim;Vardenafil IMpurity (2-Ethoxy-N-Hydroxy BenzaMidine)
• CAS NO: 879-57-2
• Molecular Formula: C₉H₁₂N₂O₂
• Molecular Weight: 180.2
• Product Categories: pharmacetical
• Mol File: 879-57-2.mol
• Article Data: 7

Chemical Properties

• Melting Point: 154-155 °C
• Boiling Point: 311.7±44.0 °C(Predicted)
• Appearance: /
• Density: 1.17±0.1 g/cm3(Predicted)
• Vapor Pressure: 0.001-0.075Pa at 25-78℃
• PKA: 14.66±0.50(Predicted)
• CAS DataBase Reference: 2-ETHOXY-N-HYDROXY-BENZAMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-ETHOXY-N-HYDROXY-BENZAMIDINE(879-57-2)
• EPA Substance Registry System: 2-ETHOXY-N-HYDROXY-BENZAMIDINE(879-57-2)

Safety Data

• Hazardous Substances Data: 879-57-2(Hazardous Substances Data)

Usage

Uses

2-Ethoxy-N''-hydroxybenzenecarboximidamide is a reagent used in the synthesis of cyclic pyrimidinones as novel inhibitors for PDE5.

Upstream product

• 6609-57-0 2-ethoxybenzonitrile 

Downstream Products

• 1597517-43-5 {(S)-2-[3-(2-ethoxyphenyl)-[1,2,4]oxadiazol-5-yl]pyrrolidin-1-yl}-(5-methyl-2-[1,2,3]triazol-2-ylphenyl)methanone 
• 913058-73-8 C₉H₁₂N₂O*C₂H₄O₂ 
• 1229019-46-8 2-(2-Ethoxyphenyl)-5-chloro-6-isopropylpyrimid-4(3H)-one 
• 1229019-45-7 2-(2-Ethoxyphenyl)-5-bromo-6-isopropylpyrimid-4(3H)-one 
• 1153409-15-4 2-(2-Ethoxyphenyl)-6-isopropylpyrimid-4(3H)-one 
• 1229017-10-0 5-chloro-6-isopropyl-2-[2-ethoxyl-5-(4-methyl-1-piperazinylsulfonyl)phenyl]pyrimid-4(3H)-one 
• 1229017-09-7 5-bromo-6-isopropyl-2-[2-ethoxyl-5-(4-methyl-1-piperazinylsulfonyl)phenyl]pyrimid-4(3H)-one 

Relevant articles and documents

Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure–Activity Relationships, and Sleep-Promoting Properties in Rats

The orexin system plays an important role in the regulation of wakefulness. Suvorexant, a dual orexin receptor antagonist (DORA) is approved for the treatment of primary insomnia. Herein, we outline our optimization efforts toward a novel DORA. We started our investigation with rac-[3-(5-chloro-benzooxazol-2-ylamino)piperidin-1-yl]-(5-methyl-2-[1,2,3]triazol-2-ylphenyl)methanone (3), a structural hybrid of suvorexant and a piperidine-containing DORA. During the optimization, we resolved liabilities such as chemical instability, CYP3A4 inhibition, and low brain penetration potential. Furthermore, structural modification of the piperidine scaffold was essential to improve potency at the orexin 2 receptor. This work led to the identification of (5-methoxy-4-methyl-2-[1,2,3]triazol-2-ylphenyl)-{(S)-2-[5-(2-trifluoromethoxyphenyl)-[1,2,4]oxadiazol-3-yl]pyrrolidin-1-yl}methanone (51), a potent, brain-penetrating DORA with in vivo efficacy similar to that of suvorexant in rats.

Phthalate oxethyl oxadiazole linked parazole compound and application thereof

The invention provides a phthalate oxethyl oxadiazole linked parazole compound. The structure of the compound is shown as a formula I (shown in the description). The compound of the formula I has a function of killing nematode, and can be used as a nemato

OXADIAZOLE DIARYL COMPOUNDS

The invention relates to compounds of formula (I): wherein R1, R2, Ra , Rb,Rc and W, have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.